Navigation Links
Rigel to Present at Three Upcoming Investor Conferences
Date:2/28/2011

SAN FRANCISCO, Feb. 28, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at three investment conferences during the month of March.  Details of each conference are as follows:Citi Global Health Care ConferenceDate:  Wednesday, March 2nd at 1:30 p.m. ETLocation:  New York, NY Cowen and Company 31st Annual Health Care ConferenceDate:  Tuesday, March 8th at 1:20 p.m. ETLocation:  Boston, MA Barclays Capital Global Healthcare ConferenceDate:  Thursday, March 17th at 10:45 a.m. ETLocation:  Miami Beach, FLAll three presentations will be webcast.  To access live audio webcast or subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral syk inhibitor that has started its phase 3 clinical trial program for RA (with AstraZeneca), and R343, an inhaled syk inhibitor in clinical trials for asthma (with Pfizer).

Contact: Ryan MaynardPhone: 650.624.1284Email: invrel@ri
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Rigel Announces Participation at Two Investor Conferences
2. Rigel to Present at JP Morgan Healthcare Conference
3. Rigel Announces Third Quarter 2009 Financial Results
4. Rigel Announces Presentations at Two Investor Conferences
5. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
6. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
7. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
8. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
9. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
10. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
11. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , August 27, 2014 ... Equipment Market By Products (Dental Radiology, CAD/CAM, Dental Chairs, Dental ... published by MarketsandMarkets, the global Dental Equipment Market is ... $5,416.3 million in 2014, growing at a CAGR ... Browse 95 market data tables and 61 figures ...
(Date:8/27/2014)... , Aug. 27, 2014 Pulse Systems, ... (EHR) , Practice Management , and Revenue Cycle ... known business practices performed by some RCM vendors, at UBM ... PA on September 19-20, 2014.  ... will return in September with a new session encouraging practices ...
(Date:8/27/2014)... HONG KONG , Aug. 27, 2014 /PRNewswire/ ... ("Sihuan Pharmaceutical" or the "Company"), a leading pharmaceutical ... franchise in China,s prescription ... of the Company and its subsidiaries (collectively the ... 2014 (the "Period"). Financial HighlightsFor the ...
Breaking Medicine Technology:Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 2Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 3Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 4Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7
... (Nasdaq: STXS ) announced today financial results for ... with the preliminary results reported on October 13, 2010. Third ... and reductions in both operating loss and net loss. ... compared to $13.3 million in the third quarter 2009. As ...
... Quality Forum (NQF) announces the election of leadership ... NQF is a unique, multi-stakeholder, nonprofit ... healthcare by setting national priorities and goals for ... and publicly reporting on performance, and promoting the ...
Cached Medicine Technology:Stereotaxis Reports Third Quarter Financial Results 2Stereotaxis Reports Third Quarter Financial Results 3Stereotaxis Reports Third Quarter Financial Results 4Stereotaxis Reports Third Quarter Financial Results 5Stereotaxis Reports Third Quarter Financial Results 6Stereotaxis Reports Third Quarter Financial Results 7National Quality Forum Members Elect New Council Leaders 2
(Date:8/27/2014)... Aug. 26, 2014 (HealthDay News) -- Health care workers ... gear to keep them safe from being infected with ... study shows. While the study was conducted before ... spring, its findings are confirmed in statistics released Monday ... health agency reported that an "unprecedented" number of health ...
(Date:8/27/2014)... and a new UCLA study has shown this is definitely ... decisions about how to treat their prostate cancer. , UCLA ... disease have a much more difficult time making treatment decisions, ... quality of their care and their long-term outcomes. , The ... can use the findings to target men less likely to ...
(Date:8/27/2014)... CIC microGUNE, the Co-operative Research Centre into ... seeks to generate innovative solutions based on ... mobility industry and life sciences, among others. ... Tecnun are collaborating with CIC microGUNE on ... funded by the Etortek 2013-2014 programme of ...
(Date:8/27/2014)... a week of tomatoes have an 18 per cent ... , With 35,000 new cases every year in the ... second most common cancer in men worldwide. , Rates ... is linked to a Westernised diet and lifestyle. , ... risk of prostate cancer, researchers at the Universities of ...
(Date:8/27/2014)... news release is available in German . ... for medical agents to treat metastatic tumors. In case of ... that is often detected late, 95% of the patients die ... develops tumor therapeutic agents that might reduce this mortality rate. ... now received a total of EUR 5 million from investors. ...
Breaking Medicine News(10 mins):Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 2Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 3Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 3Health News:Microtechnologies for driving forward mobility and human health 2Health News:Fighting prostate cancer with a tomato-rich diet 2Health News:Preclinical development of tumor therapeutic agent starts 2
... VP of Products and Marketing Will Address Growing Healthcare Trends ... Tools ... Michael Flanagan, VP of products,and marketing for Portico Systems, the ... Optimizing Provider,Network Management" at the Institute for International Research,s,conference in ...
... Barcelona, Spain: Recent political decisions have had serious ... at ECCO 14, the European Cancer Conference, today ... the Federation of European Cancer Societies (FECS) said ... take an active role in engaging with policymakers ...
... spontaneous quit attempts can be successful, PITTSBURGH, ... quit attempt may not be the path to ... for a quit attempt, a new national,survey conducted ... quitting may not require an advance plan.(1) In ...
... of Diabetic Neuropathy Market Will Be Driven by Launches, of ... ... Resources, WALTHAM, Mass., Sept. ... firms for pharmaceutical and,healthcare issues, finds that by 2016 Genentech/Roche,s Lucentis ...
... the Cure with its ... Emmy Award-winning journalist and TV personality Cristina ... Munchkin, Inc. -- maker of award-winning infant and ... again reminding women everywhere "Don,t Duck a ...
... to encourage an individual to get screened for ... according to researchers at Jefferson Medical College in ... interventions that guide recipients through the screening process ... primary care practices. , Ronald Myers, Ph.D., professor ...
Cached Medicine News:Health News:Portico Systems to Share Provider Network Management Best Practices at Institute for International Research 2Health News:Political decisions harming cancer treatment in Europe 2Health News:Photos: New Survey Shows Many Successful Quit Smoking Attempts Made Without Advance Planning 2Health News:Photos: New Survey Shows Many Successful Quit Smoking Attempts Made Without Advance Planning 3Health News:Photos: New Survey Shows Many Successful Quit Smoking Attempts Made Without Advance Planning 4Health News:Genentech/Roche's Lucentis and Eli Lilly's Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets 2Health News:Cristina Saralegui Joins Celebrities Including Matthew McConaughey, Courteney Cox and Mariska Hargitay to Raise Money for Breast Cancer Research 2Health News:Jefferson researchers find personalized interventions key to improving colon cancer screening rates 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: